Lee Stein, MD
Neurology · Cordova, TNNPI 1558392233
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $166,811 of the $212,913 with a category attached, or 78.3%. 60 manufacturers reported payments, led by Sanofi at 26.7% of the total. Reporting peaked in 2019 at $124,834 and has fallen 97.0% since, to $3,768 in 2025. Among neurology clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,316 payments — averaging $161.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$57K
- Genentech USA, Inc.$40K
- Biogen$38K
- Teva Pharmaceuticals USA, Inc.$22K
- EMD Serono, Inc.$14K
- Bristol Myers Squibb$11K
- plus $31K from 54 others
Across 381 payments — averaging $58,681 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$8.4M
- Biogen$7.7M
- Eisai Inc.$4.8M
- Genentech, Inc.$1.3M
- Novartis$183K
- Sanofi$61K
- plus $265 from 1 others
What the payments were for
- Consulting fees$13,1456%
- Speaking & faculty fees$166,81178%
- Travel & lodging$13,2116%
- Food & beverage$19,2379%
- Education$5090%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$212,913 in reported general payments places this provider in the 95th percentile of 361 neurology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 33 | $357,947 |
| Kesimpta PenOfatumumab | 29 | $260,801 |
| Rebif RebidoseInterferon Beta-1a/Albumin | 14 | $248,910 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 18 | $244,986 |
| TysabriNatalizumab | 24 | $194,228 |
| AubagioTeriflunomide | 11 | $101,074 |
| VumerityDiroximel Fumarate | 11 | $90,029 |
| Teriflunomide | 67 | $81,383 |
| RytaryCarbidopa/Levodopa | 42 | $62,507 |
| Dalfampridine ErDalfampridine | 118 | $61,421 |
| NuplazidPimavanserin Tartrate | 11 | $54,974 |
| Nurtec OdtRimegepant Sulfate | 33 | $54,878 |
| GlatopaGlatiramer Acetate | 15 | $33,786 |
| Topiramate ErTopiramate | 21 | $28,771 |
| NeurontinGabapentin | 11 | $23,244 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $321 | $357,94733 claims |
| BiogenTysabri, Vumerity | $38,027 | $284,25735 claims |
| CSL BehringPrivigen | $209 | $244,98618 claims |
| SanofiAubagio | $56,864 | $101,07411 claims |
| Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide | $348 | $65,83267 claims |
| PfizerNurtec Odt, Dilantin | $699 | $60,77471 claims |
| Acadia Pharmaceuticals IncNuplazid | $232 | $54,97411 claims |
| UCB, Inc.Vimpat | $749 | $23,01311 claims |
| AbbVieUbrelvy | $6,912 | $18,37318 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 361 neurology providers in Tennessee.
Other neurology in Cordova
- Kendrick HendersonCordova$28K
- David PritchardCordova$27K
- Oleksandra DrynCordova$26K
- Samuel HunterSpring Hill$676K
- Harold MosesNashville$438K
- Lucas ElijovichMemphis$415K
- David BrandesKnoxville$412K
- Sibyl WrayKnoxville$377K
- Christine HagenAlcoa$371K
- Mark LedouxMemphis$352K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.